FibroGen Inc
NASDAQ:FGEN
Relative Value
The Relative Value of one FGEN stock under the Base Case scenario is 8.72 USD. Compared to the current market price of 1.2 USD, FibroGen Inc is Undervalued by 86%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
FGEN Competitors Multiples
FibroGen Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
FibroGen Inc
NASDAQ:FGEN
|
111.6m USD | 0.8 | -0.4 | 0.1 | 0.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284B USD | 5.2 | 58.9 | 12.8 | 19.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
149.1B USD | 5.3 | 22.2 | 16.5 | 24.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.1B USD | 10.4 | 28.5 | 22.8 | 23.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.6B USD | 7.8 | 25.9 | 17.4 | 19.1 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.4 | 21.5 | 26.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.4B USD | 3 | 168.2 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
48B USD | 7 | -10.2 | -11 | -9.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.6 | 13.7 | 17.1 | ||
KR |
Celltrion Inc
KRX:068270
|
38.9T KRW | 18 | 73.1 | 44.4 | 61.1 |